A corrigendum on Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins
by Ha J-H, Kim J-E, Kim Y-S. Front Immunol (2016 ) 7:394. doi: 10.3389/fimmu.2016 In the original article, there was an error [wrong description on LY3164530 (Eli Lilly) antibody in the last paragraph of page 9 of original article].
A correction has been made to section "HETERODIMERIC Fc-BASED ANTIBODIES IN DIVERSE FORMATS", subsection "Intact IgG Formats with Correct LC Association", sixth Paragraph (line 8-12 of the sixth paragraph) (In the last paragraph of page 9 of original article):
An alternative approach for enforcing correct HCVH-CH1-LC association includes introduction of a set of mutations at the heterodimeric VL-CL and VH-CH1 interface (18, 66, 67) , similar to modification of the CH3 interface for the heterodimeric Fc design. In an ortho-Fab IgG approach (18), structure-based regional design introduced complementary mutations at the LC and HCVH-CH1 interface in only one Fab, without any changes being made to the other Fab (Figure 3) . Zymeworks is currently developing intact IgG-format bsAbs generated by the combination of ortho-Fab IgG and ZW1 Fc technologies (http://www.zymeworks.com/).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
